An atypical case of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-associated renal cell carcinoma identified by next-generation sequencing
Publication date: March 2018 Source:Human Pathology: Case Reports, Volume 11 Author(s): Daniel R. Matson, Molly A. Accola, William M. Rehrauer, Wei Huang Germline mutations in the fumarate hydratase (FH) gene classically lead to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome. Patients with HLRCC typically exhibit multiple cutaneous and uterine leiomyomas at a young age. They also display a 20–30% lifetime risk for renal carcinomas, which commonly present before 40years of age, have a distinct papillary morphology, and an aggressive phenotype. However, the clinical presentation of HLRCC and the morphology of HLRCC-associated renal cell carcinomas (RCCs) can be variable and thereby evade diagnosis. Here, we present two cases of HLRCC-associated RCC to emphasize this point. The first case is typical of HLRCC, involving a 29-year-old man with multiple cutaneous leiomyomas and a renal tumor with characteristic papillary morphology. Next, we describe a 48-year-old man presenting with metastatic cancer of unknown primary origin and no skin findings. Interestingly, next-generation sequencing of his metastatic tumor identified two unique FH mutations. In both cases, FH mutations were confirmed as germline. These cases highlight the variable presentations of HLRCC-associated RCC and underscore the importance of screening tumors of unknown origin for FH mutations using next-generation sequencing.
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research
Related Links:
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Dennis J. Slamon Patrick Neven Stephen Chia Peter A. Fasching Michelino De Laurentiis Seock-Ah Im Katarina Petrakova Giulia Val Bianchi Francisco J. Esteva Miguel Mart ín Arnd Nusch Gabe S. Sonke Luis De la Cruz-Merino J. Thaddeus Beck Xavier Pivot Manu Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Shanu Modi Cristina Saura Toshinari Yamashita Yeon Hee Park Sung-Bae Kim Kenji Tamura Fabrice Andre Hiroji Iwata Yoshinori Ito Junji Tsurutani Joohyuk Sohn Neelima Denduluri Christophe Perrin Kenjiro Aogi Eriko Tokunaga Seock-Ah Im Keun Seok Lee Sara A. H Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Rashmi K. Murthy Sherene Loi Alicia Okines Elisavet Paplomata Erika Hamilton Sara A. Hurvitz Nancy U. Lin Virginia Borges Vandana Abramson Carey Anders Philippe L. Bedard Mafalda Oliveira Erik Jakobsen Thomas Bachelot Shlomit S. Shachar Volkmar M üller S Source Type: research
Publication date: Available online 11 December 2019Source: The Lancet Global HealthAuthor(s): Adam Wagstaff, Sven NeelsenSummaryBackgroundThe goal of universal health coverage (UHC) requires that everyone receive needed health services, and that families who get needed services do not suffer undue financial hardship. Tracking progress towards UHC requires measurement of both these dimensions, and a way of trading them off against one another.MethodsWe measured service coverage by a weighted geometric average of four prevention indicators (antenatal care, full immunisation, and screening for breast and cervical cancers) and...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
os AC
Abstract
PURPOSE: To examine the effects of Arrabidaa chica (Bignoniacea) extract, a native plant of the Amazon known as crajiru, on a 7,12-dimethyl-1,2-benzanthracene (DMBA)-induced breast cancer model in Wistar rats.
METHODS: We compared the response of breast cancer to the oral administration of A. chica extract (ACE) for 16 weeks, associated or not with vincristine. Groups: normal control; DMBA (50mg/kg v.o,) without treatment; DMBA+ACE (300 mg/kg); DMBA+vincristine. 500μg/kg injected i.p; DMBA+ACE+Vincristine 250μg/kg i.p. Imaging by microPET and fluorescence, biochemistry, oxidative stress, ...
Source: Acta Cirurgica Brasileira - Category: Surgery Authors: Rocha KBF, Oliveira CN, Azevedo ÍM, Macedo R, Medeiros AC Tags: Acta Cir Bras Source Type: research
Triple-negative breast cancer is difficult to treat. A new study indicates that a common chemotherapy drug improves overall survival in this tumor type -- big news in cancer treatment.Medscape Medical News
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
al-Filho DC
Abstract
Carbohydrate antigen 125 (CA125) has long been used as an ovarian cancer biomarker. However, because it is not specific for ovarian cells, CA125 could also be used to monitor congestion and inflammation in heart disease. Acute heart failure (HF) is used to identify patients with a worse prognosis in ST-segment elevation myocardial infarction (STEMI). We aimed to determine the association of CA125 with acute HF in STEMI and to compare CA125 with N-terminal pro brain natriuretic peptide (NTproBNP) with a cross-sectional study. At admission, patients were examined to define Killip class and then ...
Source: Braz J Med Biol Res - Category: Research Authors: Falcão FJA, Oliveira FRA, Cantarelli F, Cantarelli R, Brito-Júnior P, Lemos H, Silva P, Camboim I, Freire MC, Carvalho O, Sobral-Filho DC Tags: Braz J Med Biol Res Source Type: research
Abstract
Polydatin (PD), a monocrystalline polyphenolic drug mainly found in the roots of Polygonum cuspidatum, has various pharmacological activities. Long non-coding RNAs (lncRNA) DiGeorge syndrome critical region gene 5 (DGCR5) was found to participate in the suppression of multiple cancers. Here, we proposed to study the effect of PD on myocardial infarction (MI) by inducing DGCR5. CCK-8 assay was performed to detect the viability of H9c2 cells. Flow cytometry was utilized to test apoptosis of H9c2 cells. These results determined the optimal concentration and effect time of hypoxia as well as PD. Si-DGCR5 was ...
Source: Braz J Med Biol Res - Category: Research Authors: Dai J, Ma J, Liao Y, Luo X, Chen G Tags: Braz J Med Biol Res Source Type: research
This study contributes with the discussion about the development of the molecular profiling of prostate cancer. The further development of similar studies could help in stratifying specific risk groups, leading to a more personalized therapeutic decision for prostate cancer treatment.
PMID: 31826177 [PubMed - in process]
Source: Braz J Med Biol Res - Category: Research Authors: Morais CE, Gurgel DC, Teixeira AC, Mattos TVA, Silva AVAD, Tavora F Tags: Braz J Med Biol Res Source Type: research
Publication date: Available online 21 November 2019Source: Best Practice &Research Clinical Obstetrics &GynaecologyAuthor(s): Mangesh A. Thorat, Rajeshkumar BalasubramanianAbstractWomen at high risk of developing breast cancer are a heterogeneous group of women including those with and without high-risk germline mutation/s. Prevention in these women requires a personalised and multidisciplinary approach. Preventive therapy with selective oestrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors (AIs) substantially reduces breast cancer risk well beyond the active treatment period. The importance...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Carcinoma of Unknown Primary | Genetics | Kidney Cancer | Leiomyoma | Pathology | Renal Cell Carcinoma | Skin
